Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active l...

• Pays Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
• Organes Aucun
• Spécialités Aucune

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment This study is to evaluate change of over active bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.

• Pays Korea, Republic of
• Organes Aucun
• Spécialités Aucune

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat ...

• Pays Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Spain, United Kingdom
• Organes Aucun
• Spécialités Aucune

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients A proof of concept study to evaluate the safety and effectiveness of FK778 in liver transplant patients.

• Pays Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Spain, Switzerland, United Kingdom
• Organes Aucun
• Spécialités Aucune